SONN Stock Overview A biotechnology company, owns a platform for biologic medicines of single or bifunctional action. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Sonnet BioTherapeutics Holdings, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Sonnet BioTherapeutics Holdings Historical stock prices Current Share Price US$1.56 52 Week High US$18.72 52 Week Low US$1.55 Beta 0.91 1 Month Change -46.58% 3 Month Change -80.50% 1 Year Change -89.11% 3 Year Change -99.86% 5 Year Change n/a Change since IPO -99.99%
Recent News & Updates Sonnet BioTherapeutics Holdings, Inc. Auditor Raises 'Going Concern' Doubt Dec 19
Sonnet BioTherapeutics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2.420243 million.
Sonnet BioTherapeutics Holdings, Inc. Announces Publication Detailing Discovery and Development of SON-1010, Albumin-Binding IL-12 Fusion Protein, Demonstrating its Mechanism of Action Dec 04 Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $5 million. Nov 08
Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $5 million. Nov 07
Sonnet BioTherapeutics Holdings, Inc. has filed a Follow-on Equity Offering. Oct 29
See more updates Sonnet BioTherapeutics Holdings, Inc. Auditor Raises 'Going Concern' Doubt Dec 19
Sonnet BioTherapeutics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2.420243 million.
Sonnet BioTherapeutics Holdings, Inc. Announces Publication Detailing Discovery and Development of SON-1010, Albumin-Binding IL-12 Fusion Protein, Demonstrating its Mechanism of Action Dec 04 Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $5 million. Nov 08
Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $5 million. Nov 07
Sonnet BioTherapeutics Holdings, Inc. has filed a Follow-on Equity Offering. Oct 29
Sonnet BioTherapeutics Regains Compliance with Nasdaq Oct 17
Sonnet BioTherapeutics Holdings, Inc Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors Sep 18
Nasdaq Hearings Panel Grants Sonnet BioTherapeutics Holdings, Inc. an Exception Until October 15, 2024 to Regain Compliance with the $1.00 Minimum Bid Price Requirement Aug 31
Nasdaq Determines to Delist Sonnet BioTherapeutics Holdings Securities Aug 11 Nasdaq Determines to Delist Sonnet BioTherapeutics Holdings Securities Aug 10
Consensus EPS estimates upgraded to US$1.95 loss May 29
Sonnet Biotherapeutics Holdings, Inc. to Present SB221 as A Trial in Progress At the Asco 2024 Annual Meeting May 29
Sonnet BioTherapeutics Holdings, Inc. Announces Updated Clinical Data for Son-1010 as Monotherapy or Combined with an Anti-Pd-L1, Along with an Increase in the Dose-Escalation Target May 23
Consensus revenue estimates increase by 42%, EPS downgraded May 21
Second quarter 2024 earnings released: EPS: US$0.079 (vs US$7.55 loss in 2Q 2023) May 16
First quarter 2024 earnings: EPS and revenues exceed analyst expectations Feb 16
Sonnet BioTherapeutics Holdings Receives Non-Compliance Notice From Nasdaq Dec 16
Full year 2023 earnings: EPS and revenues exceed analyst expectations Dec 15
New major risk - Share price stability Oct 26
Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance Sep 20
Sonnet Biotherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US Aug 17
Third quarter 2023 earnings released: US$0.13 loss per share (vs US$1.82 loss in 3Q 2022) Aug 14
Sonnet BioTherapeutics Holdings, Inc., Annual General Meeting, Aug 31, 2023 Aug 08
Sonnet Biotherapeutics Holdings, Inc. Announces Regulatory Approval for Initiation of A Clinical Trial of Son-1010 Combined with Atezolizumab Jun 21
Founder recently bought US$83k worth of stock May 17
Price target decreased by 13% to US$10.35 May 12
Consensus revenue estimates decrease by 50%, EPS upgraded Apr 24 Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $14.999777 million. Feb 10
Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering. Feb 09
Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates Feb 02
Sonnet BioTherapeutics Holdings, Inc. Announces Pharmacokinetic and Pharmacodynamic Data in A Phase 1 Dose-Escalation Trial of SON-1010 Jan 20
Price target decreased to US$25.00 Nov 16
Sonnet BioTherapeutics Holdings, Inc. Announces Interim Data in Two Phase 1 Dose-Escalation Trials of Son-1010 Nov 03
Nasdaq Listing Qualifications Staff Grants an Extension to Sonnet Oct 18
Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Oct 05
Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement Oct 04
Sonnet BioTherapeutics Holdings Inc. Appoints Lori McNeill to the Board of Directors Sep 27
Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010 Sep 22
Sonnet BioTherapeutics announces 1-for-14 reverse stock split Sep 16
Sonnet BioTherapeutics Holdings Receives Non-Compliance Letter from Nasdaq Aug 26
Consensus forecasts updated Aug 22 Sonnet BioTherapeutics Holdings, Inc. announced that it has received $2.25 million in funding Aug 16
Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia Jul 22
Price target decreased to US$2.25 Apr 27
Sonnet BioTherapeutics Holdings, Inc., Annual General Meeting, Jun 02, 2022 Apr 13
Nasdaq Grants Extension to Sonnet BioTherapeutics Holdings Till October 03, 2022 to Regain Compliance Apr 09
We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate Dec 19
Sonnet BioTherapeutics Holdings, Inc. Selects Novel Development Candidate After Completing Comparative Studies in a Mouse Melanoma Model Sep 01
Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering. Aug 21
High number of new directors Jul 31
Sonnet Bio issued U.S. patent for its albumin binding technology Jun 08
Sonnet shares rise after completing licensing agreement with New Life Therapeutics May 03
New 90-day low: US$2.07 Mar 05
New 90-day high: US$3.10 Feb 06
Sonnet BioTherapeutics reports FY results Dec 17
New 90-day high: US$2.98 Dec 07
New 90-day low: US$2.42 Sep 24
New 90-day low - US$2.46 Sep 04
New 90-day low - US$2.63 Aug 19
SONNET BioTherapeutics, Inc. completed the acquisition of Chanticleer Holdings, Inc. (NasdaqCM:BURG) in a reverse merger transaction. Jul 31
Sonnet BioTherapeutics Holdings, Inc. completed the acquisition of Relief Therapeutics SA from Relief Therapeutics Holding AG (SWX:RLF). Jul 30 Shareholder Returns SONN US Biotechs US Market 7D -13.8% -3.6% -2.4% 1Y -89.1% -2.7% 23.3%
See full shareholder returns
Return vs Industry: SONN underperformed the US Biotechs industry which returned -1.5% over the past year.
Return vs Market: SONN underperformed the US Market which returned 22.1% over the past year.
Price Volatility Is SONN's price volatile compared to industry and market? SONN volatility SONN Average Weekly Movement 16.5% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: SONN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SONN's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer.
Show more Sonnet BioTherapeutics Holdings, Inc. Fundamentals Summary How do Sonnet BioTherapeutics Holdings's earnings and revenue compare to its market cap? SONN fundamental statistics Market cap US$4.78m Earnings (TTM ) -US$7.44m Revenue (TTM ) US$18.63k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SONN income statement (TTM ) Revenue US$18.63k Cost of Revenue US$109.36k Gross Profit -US$90.73k Other Expenses US$7.35m Earnings -US$7.44m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.47 Gross Margin -487.11% Net Profit Margin -39,929.30% Debt/Equity Ratio 0%
How did SONN perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 11:27 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sonnet BioTherapeutics Holdings, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Keay Nakae Chardan Capital Markets, LLC Michael King H.C. Wainwright & Co.
Show 0 more analysts 
